<DOC>
	<DOCNO>NCT02642627</DOCNO>
	<brief_summary>This open-label , multicenter , prospective pilot study assess efficacy safety Bellafill correction distensible atrophic acne scar full facial area . All enrolled subject receive initial treatment Bellafill , well touch-up treatment ( necessary achieve optimal correction ) . Subjects evaluate Screening ( Month -1 ) , Day 0 ( Baseline ) Month 1 , Month 4 , Month 7 .</brief_summary>
	<brief_title>The Use Bellafill Atrophic Acne Scar Correction Full Facial Area</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<criteria>Outpatient , male female subject race , 21 year age old . Female subject childbearing potential must negative urine pregnancy test result Baseline practice reliable method contraception throughout study . Negative response Bellafill Skin Test . Presence ≥4 distensible atrophic acne scar ( treatment scar ) facial area . Subject desire correction his/her atrophic acne scar . All Fitzpatrick skin type eligible . Willing withhold additional aesthetic therapy propose treatment area ( e.g. , soft tissue filler hyaluronic acid , and/or resurface procedure ( describe Protocol Section 5.4 ) duration study . Able follow study instruction likely complete require visit , assess Investigator . Sign IRBapproved Informed Consent Form , Photographic Release Form , Authorization Use release Health Research Study Information ( HIPAA ) Form prior studyrelated procedure perform . Female subject pregnant ( positive urine pregnancy test ) , breastfeed , childbearing potential practicing reliable method birth control . Undergone facial treatment prohibit treatment/procedures and/or use prohibit treatment/procedure within certain time period list Protocol Section 5.4 . Excisional facial surgery ( Blepharoplasty , Face Lift , Rhinoplasty ) face le 6 month prior study enrollment plan facial surgery study . History bleed disorder . Presence skin pathology condition could interfere evaluation treatment area , worsen due propose treatment require interfere topical , systemic surgical therapy . Recent current history inflammatory skin disease , infection , cancerous/precancerous lesion , unhealed wound clinically significant acne propose treatment area . Clinically significant acne define patient ≥3 active inflammatory acne lesion treatment area . History systemic granulomatous disease active inactive ( e.g. , Sarcoid , Wegeners , TB ) connective tissue disease ( e.g. , lupus , dermatomyositis ) . Hypertrophic acne scar , evidence keloid scar treatment area . Known hypersensitivity previous allergic reaction component study device ( include lidocaine amidebased anesthetic ) , history allergy bovine collagen product , include limited injectable collagen , collagen implant , hemostatic sponge , collagenbased suture . Undergone plan undergo desensitization injection meat product . Unable communicate cooperate Investigator due language barrier ( nonEnglish speaking ) , poor mental development , impaired cerebral function . Evidence alcohol drug abuse ( Investigator opinion ) , history poor cooperation , noncompliance medical treatment , unreliability . Use investigational device , biologic drug past 30 day , currently participate experimental drug , biologic device trial . Exhibits additional physical attribute prevent assessment treatment atrophic scar , judge Investigator , excessive hair , traumatic surgical scar , excessive hyperpigmentation treatment area , etc . Has condition situation , Investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study . An employee ( relative employee ) Investigator , Sponsor representative Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>